Literature DB >> 19262961

Cost-effectiveness of post-diagnosis treatment in dementia coordinated by Multidisciplinary Memory Clinics in comparison to treatment coordinated by general practitioners: an example of a pragmatic trial.

E J Meeuwsen1, P German, R J F Melis, E M Adang, G A Golüke-Willemse, P F Krabbe, B J de Leest, F H J M van Raak, C J M Schölzel-Dorenbos, M C Visser, C A Wolfs, S Vliek, M G M Olde Rikkert.   

Abstract

BACKGROUND: With the rising number of dementia patients with associated costs and the recognition that there is room for improvement in the provision of dementia care, the question arises on how to efficiently provide high quality dementia care.
OBJECTIVE: To describe the design of a study to determine multidisciplinary memory clinics' (MMC) effectiveness and cost-effectiveness in post-diagnosis treatment and care-coordination of dementia patients and their caregivers compared to the post-diagnosis treatment and care-coordination by general practitioners (GP). Next, this article provides the theoretical background of pragmatic trials, often needed in complex interventions, with the AD- Euro study as an example of such a pragmatic approach in a clinical trial.
METHOD: The study is a pragmatic multicentre, randomised clinical trial with an economic evaluation alongside, which aims to recruit 220 independently living patients with a new dementia diagnosis and their informal caregivers. After baseline measurements, patient and caregiver are allocated to the treatment arm MMC or GP and are visited for follow up measurements at 6 and 12 months. Primary outcome measures are Health Related Quality of Life of the patient as rated by the caregiver using the Quality of Life in Alzheimer's Disease instrument (Qol-AD) and self-perceived caregiving burden of the informal caregiver measured using the Sense of Competence Questionnaire (SCQ). To establish cost-effectiveness a cost-utility analysis using utilities generated by the EuroQol instrument (EQ-5D) will be conducted from a societal perspective. Analyses will be done in an intention-to-treat fashion.
RESULTS: The inclusion period started in January 2008 and will commence until at least December 2008. After finalising follow up the results of the study are expected to be available halfway through 2010. DISCUSSION: The study will provide an answer to whether follow-up of dementia patients can best be done in specialised outpatient memory clinics or in primary care settings with regard to quality and costs. It will enable decision making on how to provide good and efficient health care services in dementia. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00554047.

Entities:  

Mesh:

Year:  2009        PMID: 19262961     DOI: 10.1007/s12603-009-0066-1

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  39 in total

Review 1.  The magnitude of dementia occurrence in the world.

Authors:  Anders Wimo; Bengt Winblad; Hedda Aguero-Torres; Eva von Strauss
Journal:  Alzheimer Dis Assoc Disord       Date:  2003 Apr-Jun       Impact factor: 2.703

2.  Cost of dementia in Europe.

Authors:  L Jönsson; C Berr
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

3.  Development of quality indicators for memory clinics.

Authors:  Irena Drasković; Myrra Vernooij-Dassen; Frans Verhey; Philip Scheltens; Marcel Olde Rikkert
Journal:  Int J Geriatr Psychiatry       Date:  2008-02       Impact factor: 3.485

4.  Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial.

Authors:  Aimee Spector; Lene Thorgrimsen; Bob Woods; Lindsay Royan; Steve Davies; Margaret Butterworth; Martin Orrell
Journal:  Br J Psychiatry       Date:  2003-09       Impact factor: 9.319

Review 5.  What are pragmatic trials?

Authors:  M Roland; D J Torgerson
Journal:  BMJ       Date:  1998-01-24

6.  The structure of coping.

Authors:  L I Pearlin; C Schooler
Journal:  J Health Soc Behav       Date:  1978-03

Review 7.  Early diagnosis of dementia: which tests are indicated? What are their costs?

Authors:  H van Crevel; W A van Gool; G J Walstra
Journal:  J Neurol       Date:  1999-02       Impact factor: 4.849

8.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

Review 9.  Cost-effective recognition and diagnosis of dementia.

Authors:  David S Geldmacher
Journal:  Semin Neurol       Date:  2002-03       Impact factor: 3.420

10.  Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity.

Authors:  Marshall Godwin; Lucia Ruhland; Ian Casson; Susan MacDonald; Dianne Delva; Richard Birtwhistle; Miu Lam; Rachelle Seguin
Journal:  BMC Med Res Methodol       Date:  2003-12-22       Impact factor: 4.615

View more
  18 in total

1.  Health economics and health policy issues in Alzheimer's disease.

Authors:  T Rapp
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Editorial: CTAD International Research Conference: Clinical Trials in Alzheimer's Disease.

Authors:  S Gauthier
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  Are memory clinics effective? The odds are in favour of their benefit, but conclusive evidence is not yet available.

Authors:  R J F Melis; E J Meeuwsen; S G Parker; M G M Olde Rikkert
Journal:  J R Soc Med       Date:  2009-11       Impact factor: 5.344

4.  Editorial: can we improve care for patients with dementia?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

5.  Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?

Authors:  Peter Makai; Willemijn Looman; Eddy Adang; René Melis; Elly Stolk; Isabelle Fabbricotti
Journal:  Eur J Health Econ       Date:  2014-04-24

6.  Clinical practice patterns of generalists and specialists in Alzheimer's disease: what are the differences, and what difference do they make?

Authors:  L Robinson; B Vellas; S Knox; K Lins
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

7.  Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation.

Authors:  A Greco; E Orlandi; A Mirabile; S Takanen; C Fallai; N A Iacovelli; A Rimedio; E Russi; M Sala; D Monzani; D I Rosenthal; G B Gunn; P Steca; L Licitra; P Bossi
Journal:  Support Care Cancer       Date:  2015-03-21       Impact factor: 3.603

8.  The primary care physician and Alzheimer's disease: an international position paper.

Authors:  H Villars; S Oustric; S Andrieu; J P Baeyens; R Bernabei; H Brodaty; K Brummel-Smith; C Celafu; N Chappell; J Fitten; G Frisoni; L Froelich; O Guerin; G Gold; I Holmerova; S Iliffe; A Lukas; R Melis; J E Morley; H Nies; F Nourhashemi; J Petermans; J Ribera Casado; L Rubenstein; A Salva; C Sieber; A Sinclair; R Schindler; E Stephan; R Y Wong; B Vellas
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

9.  Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.

Authors:  Adam Smith; Brian Giunta; Paula C Bickford; Michael Fountain; Jun Tan; R Douglas Shytle
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

10.  Patient reported outcomes in head and neck cancer: selecting instruments for quality of life integration in clinical protocols.

Authors:  Augusta P Silveira; Joaquim Gonçalves; Teresa Sequeira; Cláudia Ribeiro; Carlos Lopes; Eurico Monteiro; Francisco L Pimentel
Journal:  Head Neck Oncol       Date:  2010-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.